ADMS Adamas Pharmaceuticals Inc.

Biotech Analyst Ratings

Latest News

1. 24 November 2021 Supernus Pharmaceuticals Completes Acquisition of Adamas Pharmaceuticals

   ROCKVILLE, Md., Nov. 24, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) today announced that it has successfully completed its previously announced acquisition of Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS).
   

   "Adamas fits squarely within our corporate development strategy, adding a late-stage commercial product with significant revenue," said Jack Khattar, President and CEO of Supernus Pharmaceuticals. "In addition, the acquisition adds a new growth catalyst, diversifies our revenue base and cash flow, and is expected to be significantly accretive in 2022."

   Compelling Strategic Rationale

   • Strengthens Parkinson's disease portfolio with GOCOVRI® (amantadine) extended release capsules, the first and only FDA-approved medicine…

   View Full Article
2. 23 November 2021 Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Adamas Pharmaceuticals Tender Offer

   ROCKVILLE, Md., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) today announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) with respect to Supernus' proposed acquisition of Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) expired at 11:59 p.m. on November 22, 2021.

   On October 21, 2021, Supernus and Adamas filed the Premerger Notification and Report Forms required under the HSR Act with the Federal Trade Commission and the Antitrust Division of the U.S. Department of Justice.

   The expiration of the HSR Act waiting period satisfies one of the conditions to consummate the Offer (as defined below). The Offer continues to be subject to the remaining conditions…

   View Full Article
3. 11 October 2021 Supernus Pharmaceuticals to Acquire Adamas Pharmaceuticals Strengthening its CNS Product Portfolio

   • Acquisition of two marketed products diversifies and accelerates revenue and cash flow
     
   • Expected to be significantly accretive in 2022
   • Potential synergies of $60 million to $80 million in year one due to strong overlap with existing infrastructure
   • Total consideration up to $9.10 per share. Upfront cash payment of $8.10 per share with fully diluted equity value of approximately $400 million, plus $1.00 contingent value right based on net sales of GOCOVRI^®
   • Conference call and webcast today at 8:30 a.m. ET to discuss the transaction
     

   ROCKVILLE, Md. and EMERYVILLE, Calif., Oct. 11, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) and Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS), today announced a definitive agreement for Supernus…

   View Full Article
4. 01 October 2021 Adamas Named 2021 Finalist in the New Therapeutics Category of the UCSF Health Awards

   Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced it has been selected as one of five finalists in the UCSF Health Awards 2021 New Therapeutics category. This year's UCSF Health Awards program, which historically focused on the digital health tech industry, was expanded to include several life science categories. Companies selected as finalists have been evaluated on innovation, impact, and value of their product to improve patient outcomes. Adamas' new therapeutic is GOCOVRI® (amantadine) extended-release capsules, the first and only FDA-approved medicine indicated for the treatment of both OFF…

   View Full Article
5. 30 September 2021 Cognoa Appoints Seasoned Financial Executive, Tony Rimac, as Chief Financial Officer

   View Full Article